Drug Trial Radar · NCT05092360
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
456
Actual
Start
Jan 10, 2022
Primary completion
Jan 8, 2025
Study completion May 8, 2025
Sponsor
- Lead sponsor
- Mural Oncology, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
- Platinum-resistant Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
Nemvaleukin and Pembrolizumab CombinationBiological
Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
PembrolizumabBiological
Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
NemvaleukinBiological
Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
Pegylated Liposomal Doxorubicin (PLD)Drug
40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
PaclitaxelDrug
80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
TopotecanDrug
4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
GemcitabineDrug
1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the first dose of study drug up to 24 months
Locations
117 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Alaska Women's Cancer Care
Anchorage, Alaska
Arizona Oncology
Tucson, Arizona
University of California, San Diego (UCSD)- Moores Cancer Center
La Jolla, California
University of California, Los Angeles (UCLA)
Los Angeles, California
Ventura County Hematology- Oncology
Oxnard, California
University of Florida (UF) Health Cancer Center - Orlando Health
Orlando, Florida
Sarasota Memorial Hospital
Sarasota, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Indiana University (IU)
Indianapolis, Indiana
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
University of Maryland School of Medicine
Baltimore, Maryland
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Trinity Health Ann Arbor Hospital
Ypsilanti, Michigan
Astera Cancer Care
East Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
University of New Mexico
Albuquerque, New Mexico
Womens Cancer Care Associates
Albany, New York
Westchester Medical Center
Hawthorne, New York
NYU Langone Health
New York, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York
Vidant Medical Center
Greenville, North Carolina
University of Cincinnati (UC) - Cancer Institute
Cincinnati, Ohio
The Ohio State University (OSU)
Columbus, Ohio
Mid Ohio Oncology/Hematology, Inc. dba The Mark H. Zangmeister Center
Columbus, Ohio
Williamette Valley Cancer Institute and Research Center
Eugene, Oregon
Providence Portland Medical Center
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Avera Cancer Institute
Sioux Falls, South Dakota
Texas Oncology - Austin Central (Balcones Dr.)
Austin, Texas
Texas Oncology - DFWW (Bedford)
Bedford, Texas
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas
Baylor College of Medicine
Houston, Texas
University of Virginia - Emily Couric Cancer Center
Charlottesville, Virginia
Virginia Cancer Specialists, PC (Lake Manassas Dr)
Gainesville, Virginia
Cancer Research SA
Adelaide, Australia
Blacktown Hospital
Blacktown, Australia
Royal Brisbane and Women's Hospital
Brisbane, Australia
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.